Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Entertainment
  • Software
  • Real Estate
  • Information Technology
  • Business
Washingtoner

Study Finds Lotus Vaping Technologies' Flavored E-Liquids Reduce Smokers' Cigarettes Per Day at Significantly Higher Rate Than Tobacco Flavor
Washingtoner/10239600

Trending...
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 112
  • Tacoma: OMWBE Active Certification Class on November 16
  • Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
A rigorous three-month longitudinal cohort study of several of flavored bottled e-liquids demonstrated that those flavors were significantly more effective at reducing cigarettes smoked per day than tobacco-flavored e-liquids.

BOISE, Idaho - Washingtoner -- Lotus Vaping Technologies, LLC, a Boise, Idaho-based manufacturer of bottled e-liquids for use in electronic nicotine delivery systems ("ENDS") or e-cigarettes, announced today that a rigorous three-month longitudinal cohort study of several of its FreenomsTM branded flavored bottled e-liquids demonstrated that those flavors were significantly more effective at reducing cigarettes smoked per day than tobacco-flavored e-liquids.

The three-month study conducted from March 2023 to August 2023 involved 451 randomly assigned participants who were cigarette smokers, 221 of which were assigned to a control group that used only tobacco-flavored e-liquid, and 230 of which were assigned to a group that could use any of five different non-tobacco flavored bottled e-liquids, including Lotus's proprietary BluenomenomTM, StranomenonTM, X2 Cactus Jackfruit, and White Peach Raspberry flavors.

More on Washingtoner
  • Spokane: Mayor Brown Introduces 2027-2028 Budget Proposal
  • Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
  • IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA

At the end of three months, the average number of cigarettes smoked per day ("CPD") by the tobacco-flavored control group was reduced from 12.51 to 9.54, for a 23.72% reduction, while for the flavored e-liquid group, the average CPD was reduced from 11.70 to 6.88, for a 41.25% reduction.  The reduction in cigarettes smoked per day was thus 73.9% greater for the flavored group than the tobacco-flavored group. The study results also demonstrated statistically significant differences between several of Lotus's flavored e-liquids when compared head-to-head against tobacco-flavored e-liquids with respect to CPD reduction.

Additionally, a full 14.3% of study participants in the flavored group had quit smoking cigarettes altogether by the end of the third month—a rate that is substantially higher than that typically reported for FDA-approved nicotine replacement therapy products (9.0%).

Lotus's Director of Sales, Mike Larsen stated, "We are very excited about these study results. This study demonstrates what users of our products have known anecdotally for a long time—flavored e-liquids are more effective than tobacco flavor at promoting cigarette smoking reduction and cessation. The FDA has been asking for this data—we hope it will now take it into consideration when reviewing our premarket tobacco product applications and grant our flavored products the marketing authorizations that they deserve."

More on Washingtoner
  • Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
  • Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
  • Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
  • Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England

About Lotus Vaping Technologies, LLC – Creator of NomenonsTM E-Liquids

Established in 2013, Lotus is a leading manufacturer and wholesaler of premium e-liquids in the United States providing a diverse range of vapor products for sale to adult consumers that satisfy a wide variety of consumer preferences and serve as alternatives to combustible cigarettes. Lotus is committed to responsible manufacturing processes and utilizes only the highest standards in its e-liquid production.

Media Contact
Mike Larsen
mike@lotusecigs.com


Source: Lotus Vaping Technologies, LLC
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • International Misophonia Foundation Launches Sensory Accessible Technology Initiative to Address Overlooked Digital Accessibility Barriers
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • AI Needs Guardrails Now: A New Movement Asks People Everywhere to Take the Pledge
  • Global Leaders Convene in Seattle to Advance Responsible AI and Cross-Border Ecosystems
  • Heritage at Manalapan Announces New 3.875% First-Year Mortgage Rate Buydown (7.11 APR)
  • Haven Treatment Center Pays It Forward with Donation of 150 Food Boxes and Gift Cards to Evergreen
  • AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
  • Steve Weclew is Appointed by STS Capital Partners as Managing Director
  • ThriveStack citedby launches Prompt Research to find the prompts buyers ask in AI search
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
  • Tacoma: OMWBE Active Certification Class on November 16
  • Ornamental Designer Pro to Attend METALfab 2027, Sponsor Wednesday Opening Reception
  • The Case For Civil Disagreement
  • Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
  • AeroNet Deploys netElastic vBNG and CGNAT with Tarana Wireless to Deliver Scalable, Fiber-Class Broadband Across Puerto Rico
  • New Atlas Maps the 38 States Behind Every Conversation
  • Atlanta Company Launches Free, Ad-Free, Nonpartisan Voter Planning App for All 50 States Ahead of the Nov. 3 Election
_catLbl0 _catLbl1

Popular on Washingtoner

  • Spokane: City and Permittable Partner to Support Rebuilding After Wildfires - 272
  • Spokane: City to provide asbestos testing, host community resource meetings - 224
  • Tacoma: In-Person Workshop on October 22 for Local Businesses on the City’s Revolving Loan Fund Process - 188
  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 146
  • Final Week to Register for Free Spokane Community Conference - 126
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1 - 123
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 112
  • Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026 - 104
  • Holiday Gambling Spending Expected to Rise 12% in December - 101
  • Spokane Police Respond to Fatal Stabbing in Northeast Spokane

Similar on Washingtoner

  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Haven Treatment Center Pays It Forward with Donation of 150 Food Boxes and Gift Cards to Evergreen
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
  • Paraguay Expedition Offers a Different View of Human Resilience
  • Longevity Academy Features Gail Humble, MD of KLOTHO SKIN in the Longevity Leaders Project
  • Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
  • Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Win Gold in Raleigh's Best Awards for Second Consecutive Year
  • New Book Savvy Not Sabotaged Helps Those Hurt by Betrayal Set Boundaries Without Shutting Others Out
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute